
TELA Bio TELA
$ 0.66
-5.99%
Annual report 2025
added 03-25-2026
TELA Bio Total Assets 2011-2026 | TELA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets TELA Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81.4 M | 86.6 M | 78 M | 67.9 M | 62.5 M | 86.5 M | 67.9 M | 27.2 M | 15.5 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 86.6 M | 15.5 M | 63.7 M |
Quarterly Total Assets TELA Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.6 M | 67.5 M | 77.3 M | 86.6 M | 53 M | 60.2 M | - | 78 M | 87.3 M | 94.4 M | 58.8 M | 67.9 M | 79.6 M | 51.3 M | 55.4 M | 62.5 M | 68.8 M | 73.8 M | 78.3 M | 86.5 M | 86.5 M | 86.5 M | 86.5 M | 67.9 M | 67.9 M | 67.9 M | 67.9 M | 27.2 M | 27.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 94.4 M | 27.2 M | 69.1 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.93 | 1.02 % | $ 1.75 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.62 | -1.31 % | $ 38.6 M | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
77.2 M | $ 3.22 | - | $ 121 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 11.67 | -0.98 % | $ 330 M | ||
|
Globus Medical
GMED
|
5.3 B | $ 95.25 | 0.39 % | $ 12.9 B | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
53.8 M | $ 26.39 | -0.34 % | $ 223 M | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.28 | 5.56 % | $ 1.39 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.41 | 1.36 % | $ 385 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 5.33 | -0.09 % | $ 1.13 B | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
LivaNova PLC
LIVN
|
2.61 B | $ 63.87 | -0.51 % | $ 3.48 B | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.08 | -0.2 % | $ 60.7 M | ||
|
Pulmonx Corporation
LUNG
|
129 M | $ 1.28 | 0.79 % | $ 52.1 M | ||
|
Delcath Systems
DCTH
|
124 M | $ 10.97 | 1.2 % | $ 393 M | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.09 | 2.83 % | $ 18.5 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 39.18 | 2.08 % | $ 1.22 B | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 55.85 | -0.75 % | $ 1.64 B | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 191.14 | 0.83 % | $ 13.4 B | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 85.95 | -0.06 % | $ 2.99 B | ||
|
PAVmed
PAVM
|
38.8 M | $ 9.11 | 1.22 % | $ 6.11 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 83.94 | -0.37 % | $ 49.1 B | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 2.43 | -1.62 % | $ 6.74 M | ||
|
MiMedx Group
MDXG
|
343 M | $ 3.46 | 0.87 % | $ 511 M | ||
|
Stryker Corporation
SYK
|
47.8 B | $ 328.6 | 0.34 % | $ 126 B | ||
|
Tactile Systems Technology
TCMD
|
274 M | $ 25.34 | 1.08 % | $ 580 M | ||
|
Nevro Corp.
NVRO
|
554 M | - | - | $ 217 M |